Industry

Critical upgrades allow the Company to produce SPC-069 drug substance for clinical trials Other new additions to the facility include dedicated quality control room, microbiology laboratory and office space KNUTSFORD, England–(BUSINESS WIRE)–SpectrumX, a UK-based healthcare and pharmaceutical company, announced today that recent upgrades at its state-of-the-art production facility in Knutsford, Cheshire, will allow the Company … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 1.00% convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act … [Read more…]

The amplified iteration of the platform transforms the potential for market visibility, research collaboration and business decision-making in life science CLEVELAND & LONDON–(BUSINESS WIRE)–Within3 announces new enhancements to its industry-first insights management platform for pharmaceutical and medical device companies. With more than 40 engagement applications across the platform, life science organizations can now better understand … [Read more…]

MIAMI–(BUSINESS WIRE)–#BlueChipClients–H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with over $50 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the recapitalization of Navitas Life Sciences (“Navitas” or the “Company”). Headquartered in Princeton, NJ, Navitas is a global technology-enabled clinical research organization (CRO) providing outsourced … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “EMC Filtration Market by Product Type (EMC Filters (1-Phase EMC Filters, 3-Phase EMC Filters, DC Filters, IEC Inlets, Chokes), Power Quality Filters (Passive Harmonic Filters, Active Harmonic Filters, Output Filters, Reactors)) – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The EMC filtration market is expected to grow from USD … [Read more…]

VANCOUVER, British Columbia–(BUSINESS WIRE)–#education–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO), Revitalist and Wake Network, Inc. will now be jointly offering ketamine infusions in the United States and psilocybin clinical retreats internationally with a special focus on Veteran’s ethical need for access, establishing the world’s first international center … [Read more…]

The LARYCARE study aims at discovering new predictive biomarkers to treatment response and at developing new potential precision therapies in the larynx and hypopharynx carcinoma This study follows One Biosciences’ first discovery program initiated a year ago in partnership with Institut Curie investigating high-grade serous ovarian cancer The initiation of this study follows the completion … [Read more…]

Up-LIFT study achieves primary endpoint: Statistically significant and clinically meaningful improvement in upper extremity strength and functioni Improvement in arm and hand function is the highest priority among people with tetraplegiaii Up-LIFT is the first large-scale clinical study of non-invasive spinal cord stimulation technology ONWARD plans to submit for marketing approval in the U.S. and … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the pricing of an upsized underwritten public offering of 8,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $25.00 … [Read more…]

In less than two years, Gilead has more than doubled the cost of its HIV medication, Descovy, for the lifesaving 340B program from $445.11 in Q3, 2020 to $987.55 in Q2, 2022 AHF will host a protest Tuesday, Sept. 13th targeting Gilead Sciences—”Greediad”—and its investors over its AIDS drug pricing during the annual Morgan Stanley … [Read more…]